Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM101 in adults with active systemic lupus erythematosus with or without prior lupus nephritis
ISRCTN84672048Phase 2Completed
- Sponsor
- Baxter International Inc.
- Start
- Aug 2011
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial of valziflocept in systemic lupus erythematosus (SLE) (3 arms), sponsored by Baxter International Inc. Primary endpoint: Incidence of adverse events. Started Aug 2011; status: completed.
02
Drugs
valziflocept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ISRCTN84672048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN84672048.